Leah Fung

Company: Biotheryx

Job title: Chief Executive Officer

Seminars:

Oral, Blood-Brain Barrier Penetrant CDK4/6 Bifunctional Degrader for Breast Cancer & Other Solid Tumors  8:30 am

Highlighting Biotheryx's PRODEGY platform which has enabled the discovery of bifunctional molecules that demonstrate highly selective, rapid, and deep degradation of CDK4 and CDK6 Spotlighting BTX-9341's excellent PK/ADME properties and sustained exposure in the brain, which is currently in IND-enabling studies   Demonstrating potent tumor growth inhibition superior to the FDA-approved CDK4/6 inhibitors in breast cancer…Read more

day: Day 2 AM